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The prevalence of TARTs among men with classic CAH is estimated to be ;40% (range 14% to 89%) [3] . TARTs are thought to originate from adrenocortical primordial cells displaced and nested within the gonadal primordium and descend with the gonads during embryonic development. Morphologically and functionally, these tumors are similar to adrenal cortical tissue [4] . TARTs are typically located bilaterally near the mediastinum (rete) testes and result in mechanical obstruction of the seminiferous tubules and blood flow. Biopsies of residual testicular tissue in patients with long-standing TARTs show a decrease in tubular diameter, peritubular fibrosis, and tubular hyalinization, indicative of severe testicular damage [5] . In addition, excess adrenal androgen production in men with classic CAH can lead to hypogonadotropic hypogonadism by negative feedback.
Previous reports have described successful induction of fertility with high doses of dexamethasone of 0.75 to 1 mg daily [6, 7] . We describe successful induction of fertility with low-dose dexamethasone and subsequent twice-daily prednisone at typical recommended daily dosages, underscoring the significance of individualizing the treatment plan.
Case Description
A 28-year-old man with classic salt-wasting CAH due to 21-hydroxylase deficiency presented with subfertility. For the past 6 months, he described a minimal coital frequency of 2 or 3 times per week without the use of contraception. He had been receiving prednisone 5 mg each morning and fludrocortisone 50 mg twice daily over the last decade. He had known bilateral TARTs, first noted at age 18 and occupying 1.2% of his total testicular volume (0.38 mL of 30.68 mL) (Fig. 1) . A recent testicular ultrasound showed increased TART volume, now occupying 16% of his total testicular volume (5.01 mL of 32.30 mL testicular volume), and semen analysis showed azoospermia. On examination, the patient was short-statured, with a standing height of 153.4 cm (z score: 23.1); midparental height was 174.1 cm (z score: 20.4). Testicular volume was 25 mL bilaterally. Biochemical evaluation at 0800 before medication showed 17-hydroxyprogesterone 13,060 ng/dL (reference: 13 to 120 ng/dL), androstenedione (A4) 1025 ng/dL (reference: 26 to 125 ng/dL), ACTH 866 pg/mL (reference: 5 to 46 pg/mL), plasma renin activity (PRA) 7.1 ng/mL/h (reference: 0.6 to 4.3 ng/mL/h), FSH 1.7 U/L (reference: 1 to 11 U/L), LH 1.3 U/L (reference: 1 to 8 U/L), and total testosterone (T) 473 ng/ dL (reference: 240 to 950 ng/dL). His A4/T ratio of 2.2 (.0.5) with low LH and FSH was suggestive of a mostly adrenal origin of his T. His glucocorticoid therapy was switched from prednisone 5 mg daily to dexamethasone 250 mg at bedtime to suppress the nocturnal ACTH surge.
At his 5-month follow-up visit, he reported a weight gain of 5 kg and insomnia. Physical examination revealed supraclavicular fullness with predominantly central weight gain and the presence of abdominal striae, not present on previous exam. Testicular volume was stable at 25 mL. Repeat ultrasound showed 91% decrease in total TART volume (0.47 mL) (Fig. 1) . Follow-up semen analysis showed a sperm count of 132 3 10 6 /mL (reference range: .14 3 10 6 /mL), with 7 3 10 6 /mL being morphologically normal (reference range: .3 3 10 6 /mL) and 35% motile (normal .39%). Biochemical evaluation showed significant improvement in CAH control, with 0800 evaluation before medication revealing 17-hydroxyprogesterone 66 ng/dL, A4 16 ng/dL, ACTH 13.5 pg/mL, PRA 11 ng/mL/h, FSH 5.4 U/L, LH 1 U/L, and T 287 ng/dL ( Table 1 ). The patient's wife was confirmed to be pregnant 9 months after the initiation of dexamethasone and delivered a healthy full-term baby girl. CYP21A2 genotyping was performed. Our patient had a 30-kb deletion (CH-1 chimera subtype) in one allele and IVS2-13A/C.G (In2G) mutation in the second allele; his wife was negative for any known CYP21A2 variants, and his daughter was found to carry a 30-kb deletion (CH-1 chimera subtype) in one allele. Given his weight gain and insomnia, the patient's therapy was switched to prednisone 3 mg twice daily. He lost 3 kg, and his insomnia resolved. His TART volume, parameters of semen analysis, and biochemical markers of CAH control have remained stable 2 and a half years hence, and he is currently expecting his second child.
Discussion
This case illustrates the significance of individualizing therapy for induction of fertility in patients with CAH complicated by TARTs. Despite the use of a lower dosage of dexamethasone (250 mg daily) compared with previous reports [6, 7] , our patient experienced reversal of his infertility with dosing aimed at reducing the nighttime ACTH surge but experienced significant weight gain and insomnia. This result reflects the considerable interindividual variability in glucocorticoid metabolism and the ability of long-acting glucocorticoids, especially dexamethasone, to suppress the hypothalamic-pituitary-adrenal axis [8] and underscores the need to individualize disease management. Physicians should aim to use the lowest glucocorticoid dosage possible and evaluate for symptoms and signs of hypercortisolism irrespective of the glucocorticoid dosage. In the patient described, the TARTs showed reduction in volume with intensification of his glucocorticoid regimen. However, posterior shadowing noted on follow-up ultrasonography suggested fibrosis. Induction of fibrosis within the tumor does not occur until the end stages of TART development. Peritubular fibrosis of surrounding testicular tissue indicates early damage, potentially leading to irreversible destruction of residual parenchyma. Intensification of the glucocorticoid regimen is ineffective in shrinking the tumor size once fibrosis has occurred, because adrenal rest cells may dedifferentiate with loss of ACTH and angiotensin II dependency. Despite this evidence of potential testicular damage due to long-standing TARTs, our patient's infertility was reversed by optimizing medical management of his glucocorticoid regimen.
Patients with the severe salt-wasting form of the disease have been described to be at greater risk of TART formation, presumably because of exposure to higher concentrations of ACTH [9] . However, TARTs have been rarely described in men with nonclassic CAH [9] . Our patient's genotype and phenotype are consistent with the salt-wasting form. His short stature and biochemical profile at presentation suggest inadequate control of CAH during childhood and in the recent past. Poor CAH control has been described as a predictor of TART formation in some studies, although these findings have not been consistent [10, 11] . The presence of TART may remain occult because patients can remain asymptomatic and because these tumors are commonly not palpable until they are .2 cm because of their central location. The current Endocrine Society guideline for the management of CAH recommends screening for TARTs beginning in adolescence, with ongoing periodic monitoring to assess for development of TARTs [12] .
TARTs should be differentiated from Leydig cell tumors, the most common neoplasm of the testicular interstitial compartment, because the two share many common histological features, and misdiagnosis can result in unnecessary orchiectomy. Clinically, a history of CAH or a hormonal profile consistent with the disease, presence of bilaterality (83% in TARTs vs 3% in Leydig cell tumors), presence of Reinke crystalloids on histology, tumor shrinkage in response to intensive glucocorticoid therapy, and lack of malignant features have been used to distinguish the two.
Although biochemical profile reflects adequacy of CAH control at a snapshot in time, improvement in semen analysis parameters demonstrates adequacy of CAH control in the preceding 70 to 80 days, the time duration necessary for spermatogenesis. Initiation of dexamethasone may necessitate adjustments of fludrocortisone dosing because of the lack of mineralocorticoid activity of dexamethasone. Continued stability of the patient's biochemical, semen, and sonographic parameters on prednisone 3 mg twice daily suggests that once-daily prednisone is inadequate in controlling the ACTH-driven comorbidities in CAH, but a twice-daily prednisone regimen can improve control, probably by decreasing the nighttime ACTH surge.
Conclusion
In summary, this case illustrates successful induction of fertility in a man with TARTs by use of low-dose dexamethasone (250 mg daily) and subsequent twice-daily prednisone and underscores the importance of personalizing treatment of each patient to minimize the potential harms of glucocorticoid excess.
